<DOC>
	<DOC>NCT00556075</DOC>
	<brief_summary>The purpose of this study is to determine whether Proellex is safe and effective for the treatment of symptomatic endometriosis.</brief_summary>
	<brief_title>Safety and Efficacy Study to Evaluate Proellex in the Treatment of Premenopausal Women With Symptomatic Endometriosis</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Premenopausal women aged 1848 inclusive Endometriosis documented by laparoscopic or surgical assessment within the past ten (10) years Clinical symptoms of endometriosis for at least the past three (3) months Endometriosis symptoms Must be sexually active unless sexually inactive for endometriosisrelated dyspareunia Must have a regular or steady menstrual cycle lasting from 24 to 36 days and a detectable ovulation during the baseline period using an ovulation monitoring kit (for timing of endometrial biopsy) Other inclusion criteria may apply Six (6) months or more without a menstrual period, or Prior hysterectomy or Prior bilateral oophorectomy Diagnosis of osteopenia Present history or condition that causes nonendometriosisrelated dyspareunia Presence of excessive bleeding or menorrhagia Abnormal screening endometrial biopsy Other exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Pelvic pain</keyword>
	<keyword>Oral progesterone blocker</keyword>
</DOC>